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Respiratory distress syndromeChitosan, a cationic polysaccharide, has been found to improve the surface activity of lung surfactant extracts
in the presence of various inhibitors. It has been proposed that chitosan binds to anionic lipids (e.g.
phosphatidyl glycerols) in lung surfactants, producing stable lipid ﬁlms at the air–water interface. This
binding also reverses the net charge of the surfactant aggregates, from negative to positive. Unfortunately,
positively charged aggregates may adsorb or interact with the negatively charged epithelial tissue, leading to
poor surfactant performance. To address this issue an anionic polysaccharide, dextran sulfate (dexS), was
used as a secondary coating to reverse the charge of chitosan–lung surfactant extracts without affecting the
surface activity of the preparation. The dynamic surface tension and zeta potential of bovine lipid extract
surfactant (BLES) containing chitosan chloride (chiCl) and dexS were evaluated as a function of dexS
concentration. These studies were conducted in the absence and presence of sodium bicarbonate buffer, and
in the absence and presence of bovine serum used as model inhibitor. It was determined that using an
appropriate concentration of dexS, especially at physiological pH, it is possible to restore the negative charge
of the surfactant aggregates, and retain their surface activity, even in the presence of bovine serum. High
concentrations of dexS affect the binding of chiCl to BLES, and the surface activity of the preparation.gineering and Applied Chem-
ON, Canada M5S 3E5. Tel.: +1
a).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Lung surfactants are mixtures of phospholipids (∼85% of the
mixture), surfactant proteins (∼10%), and neutral lipids like choles-
terol (∼5%). These surfactants are secreted by Type II pnuemocytes
into the alveolar ﬂuid [1,2]. One of the main roles of lung surfactant is
to form stable ﬁlms of lipids adsorbed at the air–water interface
which, upon compression, form a semi-solid ﬁlm with near zero
surface tension. This near zero surface tension reduces the difference
in Laplace pressure among large and small alveoli, preventing lung
collapse. It has been proposed that a minimum surface tension (upon
compression) of 5 mJ/m2 or lower is necessary to prevent lung
collapse [3]. Unfortunately, the lack of lung surfactant (common in
pre-term neonates) or its malfunction in the presence of inhibitors
such as blood proteins, unsaturated fatty acids or lysolecithins
increase the risk for lung collapse and poor blood oxygenation, a
condition known as respiratory distress syndrome (RDS).
Surfactant replacement therapy, which involves instilling surfac-
tants extracted from the lungs of swine and cattle into the lungs of the
patient, has been successful in neonatal-RDS (or nRDS) whencombined with appropriate ventilation techniques [4,5]. However,
this therapy is still ineffective to reduce the mortality of patients with
dysfunctional surfactant, a condition also known as acute-RDS or
ARDS [6].
In the development of new, more effective surfactant therapies
one needs to consider the differences in composition between the
fully functional (complete) lung surfactants, and the composition of
lung surfactant extracts. The current methods of surfactant extraction
use organic solvents that completely remove the hydrophilic
surfactant proteins SP-A and SP-D, as well as a fraction of the
hydrophobic, and cationic surfactant proteins SP-B and SP-C [2,5]. The
surfactant protein SP-A is negatively charged at the physiological pH
of 6.9, and it is involved in the stabilization of lung surfactant
aggregates in tubular myelin [7,8]. On the other hand, surfactant
proteins SP-B and SP-C are positively charged at pH 6.9. Complete lack
of surfactant protein SP-B is lethal [9,10]. Furthermore, SP-B and SP-C
are said to interact with the anionic lipids (phosphatidyl glycerols) of
lung surfactant to stabilize the tubular myelin and the surfactant ﬁlm
at the air–water interface [11,12].
Nonionic polymers such as dextran and polyethylene glycol have
been used, in part inspired by SP-A, to induce the formation of large
surface active surfactant aggregates [13–15]. These nonionic polymers
are effective in accelerating the adsorption of surfactant aggregates in
vitro, but there are conﬂicting results in vivo [16]. When evaluated in
fully humid environment (100% RH) polyethylene glycol is ineffective
Fig. 1. Schematic of the hypothetical binding between the anionic lipids in BLES,
represented by dipalmitoyl phosphatidyl glycerol (DDPG) with chitosan chloride
(chiCl, protasan) and dextran sulfate (dexS).
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hyaluronan) have also been evaluated and shown to bemore effective
than nonionic polymers [18,19].
Additives that could emulate the hydrophobic and cationic nature
of SP-B and SP-C have also been considered. A synthetic lysine–
leucine cationic peptide, KL4, has been used as a SP-B analog;
recombinant forms of SP-C, and the cationic lipopeptide polymyxin
B have all improved the properties of lung surfactant extracts in the
presence of various inhibitors [20–23].
More recently, chitosan base (or simply chitosan), a cationic
polysaccharide has been used as additive in lung surfactant formula-
tions, ﬁnding that it is up to 1000 times more effective than the
nonionic polyethylene glycol in reversing surfactant inhibition
associated with albumin [24,25]. Furthermore, mixtures of BLES and
chitosan in its hydrochloride form (protasan or chitosan chloride,
chiCl) have been found to retain their surface activity in the presence
of albumin, cholesterol, ﬁbrinogen, and cholesterol, and reverse the
inhibitory action of serum [26]. The difference between ChiCl and
chitosan base is that the base only ionizes and dissolves at low enough
pHs, whereas the hydrochloride form was turned into a soluble
chloride salt form by dissolving the chitosan base in hydrochloric acid,
followed by lyophilization of the resulting salt.
It has been proposed that the enhancement of the surface activity
of the extracts with the addition of cationic additives is associated
with the binding of the cationic groups of the additive to patches of
anionic lipids such as phosphatidyl glycerols [2,25]. This hypothesis is
supported by thermodynamic models that explain the binding of
cationic peptides to anionic lipids [27].
There have been several studies that show that most cationic
additives, in particular chitosan base and chiCl, do not produce any
toxic effect onbronchoalveolar tissue cultures [24,28,29].However, there
is one aspect that needs further consideration, i.e. the fact that when
using cationic additives, and in particular chitosans, the charge of the
surfactant aggregates is affected. The most signiﬁcant change in this
chargehasbeen reported forBLESpreparations formulatedwith chitosan
base (i.e. not the hydrochloride form). In that case, the zeta potential of
the surfactant aggregates changed from values near−15 mV to values
close to +20 mV for optimal chitosan base-BLES formulations [25]. This
modiﬁcation of the charge of the aggregates may create signiﬁcant
changes in the way these aggregates interact with the rest of the
components of the alveolar ﬂuid and the alveolar epithelial tissue itself.
In fact, in drug delivery applications, originally negatively charged
nanoparticles are purposely turned positive with the aid of chitosans, to
improve uptake by epithelial tissue [30]. Similarly, we have observed, in
preliminary studies that upon contact with epithelial tissue, a partial
(and sometimes total) disappearance of positively charged aggregates
[31]. Furthermore, other cationic proteins or polyelectrolytes used in
various medical treatments sometimes create problems including
exacerbated response of the immune systems and lung edema [32–35].
In order to take advantage of the wide range of cationic additives
for lung surfactant extracts, it is necessary to minimize the risks
associated with these additives by modifying the charge of these
surfactant–additive complexes. To meet this challenge, it is useful to
turn the attention to the layer-by-layer polyelectrolyte assembly
technique initially introduced by Decher et al. [36,37]. According to
this technique, by sequentially adsorbing layers of anionic and
cationic polymers over a surface it is possible to create “fuzzy” thin
ﬁlms with either negative or positive charges, depending on the
number of layers applied. This approach has been used in numerous
applications, including drug delivery and tissue engineering [38].
Before selecting a suitable anionic polyelectrolyte it is necessary to
consider the interaction between chitosan and epithelial tissue.
Several researchers interested in drug delivery applications have
studied the binding of chitosan to mucin (anionic polyssacharide
secreted by some epithelial cells) to understand the binding of
chitosan-coated particles to tissue [39–41]. The work of Qaqish andAmiji is of particular interest because they found that the binding of
mucin to chitosan is relatively weak compared to the binding of dexS
(dexS) to chitosan [39]. This implies that if chitosan is exposed to dexS
it will preferentially adsorb to this polyelectrolyte rather than
adsorbing onto the mucin-coated epithelial tissue. Therefore, in this
work, dexS is used to reverse the charge of BLES–chiCl preparations.
Fig. 1 presents a schematic illustrating this idea. Furthermore, it is
hypothesized that this change in the charge of the surfactant
aggregates should not affect their surface activity. In the ﬁrst part of
this work, the zeta potential and surface activity of BLES–chiCl
preparations are evaluated as a function of dexS concentration. The
surface activity was evaluated using a constrained sessile drop (CSD)
cycled to simulate the compression–expansion cycles during normal
breathing conditions [42,43]. To evaluate the ability of these
preparations to remain active in the presence of inhibitors, their
activity was evaluated in the presence of bovine serum [44,45]. These
studies were repeated in the presence of sodium bicarbonate used to
simulate the physiological pH.
2. Materials and methods
2.1. Materials
BLES (Bovine Lipid Extract Surfactant) was provided by BLES
Biochemicals Inc., London, Ontario, Canada. BLES contains mainly
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Concentrated (27 mg/ml) BLES samples were stored as an aqueous
suspension in glass vials under N2 atmosphere at−20 °C until the day
of the experiment. For all experiments, except those presented in
Table 1, a BLES batch received in Winter of 2008 was used. The
experiments of Table 1 were conducted using a BLES batch received in
Fall of 2009.
Chitosan hydrochloride (Protasan Cl) 213 kDawas purchased from
Novamatrix (Norway) (ProtasanUP Test Kit, #4219001). Thesewater-
soluble chitosans have a degree of deacetylation of 75–90%. Protasan
213 contains molecules ranging from 150,000 to 400,000 g/mol.
Dextran sulfate 500 kDa (product # D8906), sodium bicarbonate, and
bovine serum (B8655, 60 mg/ml protein) were also purchased from
Sigma-Aldrich (Oakville, Canada).
2.2. Methods
2.2.1. Sample preparation
Frozen BLES (27 mg lipids/ml as received) samples were thawed
in a 37.5 °C water bath for 1 h, before being diluted using a salt
solution containing 0.6% NaCl and 1.5 mM CaCl2. The concentration of
calcium chloride is important because, similarly to chitosan, it binds to
anionic lipids; the concentration used in this work is representative of
the levels found to in the alveolar ﬂuid in plasma [46,47]. The
prescribed amount of a stock solution of chitosan chloride (1 mg/ml)
was added in the NaCl/CaCl2 salt solution. The pH of the resulting
BLES–chitosan chloride was 5.4±0.1. The concentration of BLES was
2 mg/ml in all preparations. The concentration of chitosan chloride
was 0.15 mg/ml. Finally, the prescribed volume of bovine serum was
added to the surfactant mixture. The ﬁnal pH of these BLES–chitosan
chloride-serum mixtures was 6.9±0.1. For systems involving sodium
bicarbonate the order of addition was: BLES+electrolyte solution+
chitosan chloride+bicarbonate+bovine serum.
2.2.2. Surface tension measurements
The surface activity of BLES–chitosan chloride-serum preparations
was evaluated using a Constrained Sessile Drop (CSD) surfactometer
in conjunction with Axisymmetric Drop Shape Analysis (ADSA). The
design and operation of the CSD device has been described in detail
elsewhere [24,25,43]. Brieﬂy, to start any CSD operation, a sessile drop
of the test liquid is formed on a circular horizontal surface of a
stainless steel pedestal (3 mm diameter). The pedestal has a sharp-
knife edge (60° angle of approach) to prevent the spreading of the test
liquid when the surface tension reaches a near zero value at the end of
the compression stage. During the experiments, the droplet is
enclosed in a chamber with controlled temperature (37 °C) and
humidity (100% relative humidity). After the drop is formed, it is
undisturbed until the equilibrium surface tension of ∼25 mJ/m2 is
reached (typically completed in 3 min). After that time, the surfactant
suspension is injected into and out of the droplet, via a motor-
controlled syringe, to produce dynamic expansion and compression
cycles of the droplet with a periodicity of 3 s/cycle. The ratio betweenTable 1
Dynamic surface tension properties (minimum interfacial tension and elasticity) of
formulations prepared with 2 mg/ml BLES, 0.15 mg/ml Protasan 213 kDa, and the
prescribed concentrations of dextran sulfate (dexS) and sodium bicarbonate (NaHCO3).
Dynamic compression conditions: 3 s/cycle, 20% compression in 100% R.H. air.
DexS NaHCO3 pH 1h−γmin 3h−γmin 1h−ε 3h−ε ζ
mg/ml mM mJ/m2 mJ/m2 mJ/m2 mJ/m2 mV
0 0 5.29 2.6±0.7 2.1±0.1 143±6 164±7 +28±9
0 0.4 6.4 8.1±1.9 15±1 80±36 45±2 −7±9
0 1.5 6.98 17±1 16.8±0.1 8±7 35±3 −12±9
0.04 0 5.38 3.3±0.3 2.5±0.2 127±13 138±2 +13±5
0.04 0.4 6.4 5.4±0.6 17.6±0.1 99±12 20±3 −5±6
0.04 1.5 7.09 5.6±2.2 3.6±0.3 74±14 124±7 −14±3the drop area at the end of compression to the initial drop area was
adjusted to approximately 80% (equivalent to 20% area compression),
in order to mimic normal breathing in adults [1,43]. Images of the
drop (20 images/s) during dynamic cycling were collected by a CCD
camera (Model 4815-5000, Cohu Corp., Poway, CA). The acquired
imageswere processed by a digital video processor (Snapper-8, Active
Silicon LTD) and stored in a workstation to be later analyzed by ADSA
to calculate the surface tension, surface area and volume of the drop
during the cycle [25,42,43]. The results are expressed as the mean±
95% conﬁdence interval (n≥4 unless otherwise indicated). Typical
surface tension – volume – area output of ADSA for 2.0 mg/ml BLES+
0.15 mg/ml chiCl and 50 μl/ml serum and for complete lung
surfactant-serum during dynamic cycling are presented in Fig. 2.
2.2.3. Zeta potential measurements
The zeta potential of the surfactant aggregates was determined
using a Delsa 440SX Zeta Potential Analyzer (Coulter-Beckman,
Miami, FL). To prevent the saturation of the light scattering detectors,
each sample was diluted by a factor of 10 in a 0.9% NaCl solution.
Additional information on this method is available elsewhere [25].
2.2.4. Dilatational elasticity (ε)
The dilatational elasticity (ε) quantiﬁes the ability of a surfactant
ﬁlm to reduce the surface tension (γ) for a given compression
(reduction in surface area), such that ε=dγ/(dA/A)=dγ/d(lnA). In
terms of fractional area(A/Ao), then ε=dγ/dln(A/Ao) where Ao is
the maximum surface area of the bubble . To calculate dγ/dln(A/Ao)
the compression stage of the 3rd cycle was considered, which
corresponds to the steady state performance of the ﬁlm. The data of
γ versus ln(A/Ao) for that compression were ﬁtted to a 4th orderFig. 2. Surface tension – Area – Volume output of ADSA for 2.0 mg/ml BLES+0.15 mg/
ml chiCl (chitosan chloride, protasan), in the presence of 50 μl/ml of bovine serum.
Cycling conditions: 3 s/cycle periodicity, ∼20% area reduction, 37 °C, 100% relative
humidity. Stages 1–4 of the compression cycle are shown.
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evaluated at half compression. Further details of this calculation are
provided elsewhere [25,43]. Further to reporting the elasticity of the
surfactant ﬁlms, in some cases the onset of ﬁlm collapse is also
reported. This ﬁlm collapse occurs when further reduction of surface
area of the drop does not yield a reduction in surface tension (this is
equivalent to a ﬁlm elasticity of zero during that part of the
compression) [1].
3. Results
3.1. BLES–chitosan chloride (chiCl)–dextran sulfate (dexS)
Fig. 2 presents a typical ADSA output of a dynamic cycling
experiment for a system containing 2 mg/ml BLES, 0.15 mg/ml chiCl
(213 kDa) and 50 μl/ml of bovine serum used as a model inhibitor.
This ratio of BLES and chiCl was found to be optimal in a previous
study [26]. Fig. 2 shows the four stages of the dynamic cycling
experiment. In stage 1 (adsorption) the surfactant adsorbs/spreads at
the air–water interface and the surface tension approaches the
equilibrium surface tension while the volume of the drop is held
constant. In stage 2 (compression), liquid is drawn from the droplet,
reducing the volume and surface area of the drop, and the surface
tension of the suspension. At the end of this compression stage the
surface tension of this formulation should be equal to or lower than
5 mJ/m2 to minimize the risk of lung collapse [1,2]. During the
compression stage it is also desirable to obtain the largest possible
reduction in surface tension with a minimum reduction in surface
area in order to prevent over-distending the lungs. The ratio between
the surface tension reduction (dγ) and the reduction of surface area
(dA) is expressed in terms of dilatational elasticity of the ﬁlm (ε) [25].
In stage 3 (relaxation) the volume of the drop and surface area remain
approximately constant, and the surface tension of the ﬁlm may
increase (relax) if the ﬁlm is not completely stable, as in the case of
Fig. 2. In stage 4 (expansion) liquid is injected into the drop which
increases the volume, surface area and surface tension of the drop. In
this work, the performance of the BLES–chitosan formulation of Fig. 2
is used as a benchmark for surface activity. It is necessary to verify that
the modiﬁcation of the BLES–chiCl formulation with the anionic
polysaccharide, dexS, does not affect the surface activity of the
formulation alone or in the presence of the inhibitor (serum).
Fig. 3 presents the zeta potential of surfactant aggregates prepared
with 2 mg/ml BLES, 0.15 mg/ml Chitosan (same base preparation of
Fig. 2) as a function of concentration of dexS. The data in Fig. 3 conﬁrm
that dextran-free BLES–chiCl formulations produce positively charged
aggregates, as in the case of BLES and chitosan base [25]. In those
cases, the positive charge of the aggregates has been associated with
the unbound positively charged amino groups in chitosan [25]. The
hypothesis was that the negatively charged groups in dexS would
bind to the positive charges in chitosan and eventually reverse the
charge of the aggregate, according to the schematic of Fig. 1. The dataFig. 3. Zeta potential of preparations containing 2.0 mg/ml BLES+0.15 mg/ml chiCl
(protasan) in saline solution, as a function of dexS concentration.in Fig. 3 support this hypothesis since increasing the concentration of
dexS the zeta potential of the surfactant aggregates shifts towards
negative values, and eventually reverses when 0.06 mg/ml of dexS is
added. After that charge reversal point, further increase in the
concentration of dexS only results in marginal decreases in zeta
potential.
To evaluate the effect of the addition of dexS on the surface
activity, dynamic cycling experiments were conducted with formula-
tions prepared with 2.0 mg/ml BLES+0.15 mg/ml chiCl and different
concentrations of dexS. Fig. 4 presents the minimum surface tension
of these preparations as a function of dexS concentration. At
intermediate dexS concentrations (0.02 mg/ml and 0.04 mg/ml)
there is a slight increase in the minimum surface tension, however,
at the concentration of 0.06 mg/ml of dexS the minimum surface
tension reached a value close to that of BLES–chiCl alone (∼3 mJ/m2).
At concentrations of 0.08 and 0.1 mg/ml of dexS theminimum surface
tension increases substantially.
In order to understand the observed changes in minimum surface
tension with the addition of dexS, the surface tension-area cycling
isotherms for systems containing 0, 0.06 mg/ml and 0.1 mg/ml dexS
are presented in Fig. 5. According to that ﬁgure, the system of BLES and
chiCl alone responds quitewell to the compression as it achieves near 2
to 3 mJ/m2 at about 15% compression (reduction of the initial area of
the drop,A/Ao=0.85). On the other hand, the system formulatedwith
0.06 mg/ml dexS requires a 20% compression (A/Ao=0.80) in order
to achieve a similar surface tension. However, the preparation
containing 0.1 mg/ml dexS does not adsorb well (surface tension
before compression near 40 mJ/m2) and the surfactant ﬁlm seems to
collapse at a surface tension of 20 mJ/m2. Further to these observa-
tions, the calculated elasticity (ε) of the BLES–chiCl system is 130 mJ/
m2, the elasticity of the system containing 0.06 mg/ml dexS is 120 mJ/
m2, and the system containing 0.1 mg/ml dexS is 90 mJ/m2. These
values are consistent with previous ﬁndings for chitosan base and
BLES, where the most active systems can reach elasticity values
ranging from 120 to 200 mJ/m2, and BLES-only systems have an
elasticity near 80 mJ/m2 [25,43].
3.2. BLES–chiCl–dexS in serum
To study the activity of the BLES–chiCl systemwithdexS in 50 μl/ml
serum (model inhibitor), zeta potential and dynamic cycling experi-
mentswere conducted for the formulations of Fig. 3. The zeta potential
of these BLES–ChiCl–dexS-serum systems is presented in Fig. 6 as aFig. 4. Minimum surface tension of formulations containing 2.0 mg/ml BLES+0.15 mg/
ml chiCl (protasan), as a functionofdexS concentration. Compression conditionsdescribed
in Fig. 2.
Fig. 5. Surface tension – relative interfacial area (cycling) isotherm for formulations
containing 2.0 mg/ml BLES+0.15 mg/ml chiCl (protasan) and 0, 0.06, and 0.1 mg/ml
dexS, compressed at 3 s/cycle, 100% R.H., 37 °C.
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presence of serum, the zeta potential of BLES–chiCl is reduced from
+20 mV to about +5 mV. This change in zeta potential is due to the
fact that serum contains bovine albumin and other biomolecules that
serve as buffers (pH of the suspension to a pH of 6.9±0.1).Fig. 6. Zeta potential of preparations containing 2.0 mg/ml BLES+0.15 mg/ml chiCl
(protasan) in saline solution, as a function of dexS concentration, in the presence of
50 μl/ml of bovine serum.Furthermore some of the proteins in serum, mainly albumin, are
negatively charged and they could adsorb on the positive groups in
chitosan. However, the binding of albumin to chitosan is relatively
weak [39]. Serum proteins could also insert themselves in the
surfactant membrane. The reduction in zeta potential values with
increasing dexS concentration reaches a plateau at a concentration of
0.04 mg/ml dexS.
The dynamic cycling isotherms of selected BLES–chiCl–dexS
formulations in serum are presented in Fig. 7. The top part of the
ﬁgure (no dexS) corresponds to the same system as Fig. 2. That BLES–
chiCl system reaches a minimum surface tension of 5 mJ/m2, and
maintains a dilatational elasticity of 120 mJ/m2. In the presence of
0.02 mg/ml dexS the system does not appear to undergo ﬁlm collapse
but the elasticity reduces to 70 mJ/m2 and the ﬁlm is highly unstable,
as shown by the large surface tension relaxation at the end of the
compression cycle. This instability is responsible for the hysteresis in
the compression cycle. For the preparation containing 0.06 mg/ml
dexS (an optimal formulation in the absence of serum), the surfactant
ﬁlm collapses at a surface tension of 18 mJ/m2.Fig. 7. Surface tension – relative interfacial area (cycling) isotherm for formulations
containing 2.0 mg/ml BLES+0.15 mg/ml chiCl (protasan) and 0, 0.02 and 0.06 mg/ml
dexS in the presence of 50 μl/ml of bovine serum. These systems were compressed at
3 s/cycle, 100% R.H., 37 °C.
Fig. 9. Surface tension – relative interfacial area (cycling) isotherm for formulations
containing 2.0 mg/ml BLES+0.15 mg/ml chiCl (protasan) and 0, 0.04 and 0.06 mg/ml
dexS in the presence of 1.2 mM sodium bicarbonate. These systemswere compressed at
3 s/cycle, 100% R.H., 37 °C.
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As will be explained in more detail in the Discussion section, the
poor surface activity observed with systems containing high dexS
concentration might be linked to the high binding afﬁnity between
chitosan and dexS. This ChiCl–dexS binding may remove chiCl from
the BLES–chiCl. Based on the observations of Fig. 6, it is possible that
increasing the pH of the system (one of the effects of adding serum to
the system) may lead to more negative zeta potentials and lower
necessary dexS concentrations to reverse the charge of BLES–chitosan
aggregates. To test this hypothesis and observe the effect of pH on zeta
potential, the zeta potential and surface activity of BLES–chiCl–dexS
preparations was evaluated in the presence of 1.2 mM of sodium
bicarbonate. This concentration of sodium bicarbonate is compatible
with bicarbonate concentrations measured in the lungs and with
previous studies with lung surfactants [1]. Fig. 8 presents the zeta
potential of these systems as a function of dexS concentration. The
addition of 1.2 mM of bicarbonate decreased the zeta potential of the
BLES–chiCl aggregates from +20 mV (Fig. 3) to +7 mV (Fig. 8).
Furthermore, the dexS concentration required to reverse the charge of
BLES–chiCl was reduced from 0.06 mg/ml (Fig. 3) to about 0.03 mg/
ml (Fig. 8). According to Fig. 8, the zeta potential of the system
containing 0.06 mg/ml DexS and 1.2 mM bicarbonate is −15 mV,
close to the zeta potential of the original surfactant aggregates [25].
The dynamic cycling isotherms of selected BLES–chiCl–dexS systems
in the presence of 1.2 mM of bicarbonate are presented in Fig. 9. In this
case, all the formulations can reach surface tensions near or even below
5 mJ/m2 and that there is no evidence of ﬁlm collapse. For the system
BLES–chiCl–bicarbonate, the elasticity of that ﬁlm is 130 mJ/m2. That
system also has the largest ﬁlm relaxation, which suggests that the
BLES–chiCl–bicarbonate systems are somewhat unstable. The formula-
tion prepared with 0.04 mg/ml dexS has an elasticity of 125 mJ/m2.
The elasticity of the preparation with 0.06 mg/ml dextrate sulfate is
93 mJ/m2.
A second series of BLES–chiCl–dexS–bicarbonate formulations was
evaluated using a different batch of BLES (fall of 2009) to evaluate the
effect of pH, and time in more detail. A summary of the minimum
surface tension and elasticity after 1 and 3 h of preparation is included
in Table 1 for formulations containing 0, 0.4 and 1.5 mM of
bicarbonate, and 0 and 0.04 mg/ml dextran sulfate. Table 1 also
includes the pH and zeta potential of these formulations. For the
system of BLES–chiCl the minimum surface tension in Table 1 is
similar to the BLES–chiCl systems obtained with the previous batch of
BLES (see Fig. 4). The performance of this formulation tends to slightly
improve between 1 and 3 h after preparation. However, for BLES–
chiCl–bicarbonate systems the increase in pH from 5.3 to 6.4 and 7.0
with the addition of 0.4 and 1.5 mM of bicarbonate brings about an
increase in the minimum surface tension, and a reduction in the zeta
potential. Comparingwith the results of the previous batch (top graphFig. 8. Zeta potential of preparations containing 2.0 mg/ml BLES+0.15 mg/ml chiCl
(protasan) in saline solution containing 1.2 mM of sodium bicarbonate, as a function of
dexS concentration.of Fig. 9), the batch of fall 2009 is more susceptible to the addition of
bicarbonate.
Another observation from Table 1 is that the addition of dextran
sulfate produced negligible changes in pH, but it produced a modest
reduction in the zeta potential of the surfactant aggregates. The
system of BLES–chiCl–dexS–0.4 mM bicarbonate produced a relative
low minimum surface tension of 5.4 mJ/m2 after 1 h of preparation,
but this tension eventually rose to 17.6 mJ/m2 after 3 h. This increase
in minimum surface tension was accompanied by the formation of
large ﬂocks that settled at the bottom of the syringe used to inject the
surfactant solution into the CSD device. The formation of these large
ﬂocks is consistent with the near zero zeta potential of this
formulation. The system of BLES–chiCl–dexS–1.5 mM bicarbonate
produced a minimum surface tension of 5.6 mJ/m2 after 1 h of
preparation that reduced to 3.6 mJ/m2 after 3 h. This formulation
retained a “milky” appearance throughout the course of the
experiment, which is consistent with the formation of stable
aggregates with negative zeta potential of −14 mV. The formulation
containing 0.04 mg/ml dexS and 1.5 mM bicarbonate prepared with
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prepared with 0.04 mg/ml dexS and 1.2 mM bicarbonate and the
previous BLES batch, suggesting robustness of this particular
combination. Systems with 0.06 mg/ml dexS and the Sept. 2009
BLES batch (results not shown) produced formulations with high
minimum surface tensions (N15 mJ/m2). Such behavior was observed
in the previous BLES batch at a concentration of 0.08 mg/ml dexS
(Fig. 4).
3.4. BLES–chiCl–dexS–bicarbonate-serum systems
To evaluate if these formulations containing sodium bicarbonate
can remain surface active in the presence of serum, dynamic cycling
studieswere carried out using the same systems of Fig. 9, but including
50 μl/ml serum in the preparation. The resulting dynamic cycling
isotherms are presented in Fig. 10. All the formulations shown in
Fig. 10 can reach minimum surface tensions lower than 5 mJ/m2Fig. 10. Surface tension – relative interfacial area (cycling) isotherm for formulations
containing 2.0 mg/ml BLES+0.15 mg/ml chiCl (protasan) and 0, 0.04 and 0.06 mg/ml
dexS in the presence of 1.2 mM sodium bicarbonate, and 50 μl/ml of bovine serum.
These systems were compressed at 3 s/cycle, 100% R.H., 37 °C.without showing signs of ﬁlm collapse. The system of BLES–chiCl (no
dexS) shows signs of signiﬁcant surface tension relaxation. The
elasticity of that system is 122 mJ/m2, and that level of elasticity is
maintained in the presence of dexS (ε=127 mJ/m2 and130 mJ/m2 for
0.04 mg/ml and 0.06 mg/ml dexS, respectively). The zeta potential of
the BLES–chiCl (no dexS) system was close to 0 mV whereas the zeta
potential of the system containing 0.04 mg/ml dexS was−10 mV and
that the system containing 0.06 mg/ml of dexS was close to−18 mV.
The combination of BLES, chiCl, dexS in bicarbonate buffered
solution is capable of remaining surface active and negatively charged
at physiologically relevant conditions and in the presence of bovine
serum used as model inhibitor. BLEX–chiCl–dexS at pH 6.9 form stable
“milky” suspensions that resemble the colloidal stability of the
original lung surfactants.
4. Discussion
The binding between the anionic lipid (DPPG) and chitosan
proposed in Fig. 1 is compatible with a patch adsorption concept
proposed to explain the binding of anionic lipids to cationic proteins
and later extended to BLES–chitosan systems [25,27]. According to
that concept, the chitosan binds preferentially to patches of anionic
lipids in the lung surfactant aggregates, and in lung surfactant ﬁlms
adsorbed at the air–water interface [25]. It has been proposed that the
optimal ratio between chitosan and BLES is obtained when the area
occupied by the molecules of the anionic lipids is equal to the area
occupied by the chitosan. From that ratio, it was proposed that
approximately 3 positively charged glucosamine groups of chitosan
(assuming complete dissociation and deacetylation of chitosan) bind
to two molecules of the anionic lipid (DPPG or a DPPG-like molecule),
each carrying one negative charge.
Dextran sulfate (dexS) used in this work is extracted from bacterial
cultures, and therefore there is not a ﬁxed molecular structure that
can be used to represent the molecule. The structure presented in
Fig. 1 shows the basic backbone of dexS, and the fact that each glucose
unit can contain one or more sulfate groups. The supplier of dexS
indicates that there are approximately 2 sulfate groups for each
glucose unit [48].
The literature on polyelectrolyte complexes (PEC) of dexS and
chitosan suggests that when the number of positive charges of
chitosan (n+) is equal to the number of negative charges in dexS (n−),
i.e. at n−/n+=1, large net-zero charge ﬂocks of PEC form and
ﬂocculate, and that at other ratios smaller PEC particles form with
either net positive or negative charge [39,49–51]. In this work, chiCl is
already pre-adsorbed to the surfactant aggregates, and according to
the optimal binding ratio discussed above and illustrated in Fig. 1, only
one third of the positive charges are available for binding with dexS,
and therefore one would expect a net-zero charge when n−/n+=1/
3. To test these ideas, the zeta potential values of Fig. 3 were plotted as
a function of the n-/n+ ratio. The value of n+ was calculated based on
the concentration of chiCl in the preparation (0.15 mg/ml), the
weight of the repeating unit (glucosamine hydrochloride, 215 g/mol)
assuming 100% deacetylation and 100% dissociation. The value of n−
was calculated based on the concentration of dexS, the weight of the
repeating unit (a disulfate glucose unit, 365 g/mol), and assuming
that there are 2 negative charges per repeating unit.
Fig. 11 presents the zeta potential and elasticity values for BLES–
chiCl–dexSpreparations versus the calculatedn−/n+ratio. According to
this ﬁgure, the charge of the aggregates reverses for an n−/n+ ratio of
0.5, which is certainly lower than the value of 1 expected for chiCl–dexS
complexes but is still higher than the expected value of 0.33 for BLES–
chiCl–dexS. This suggests that a fraction of chitosan forms BLES–chiCl–
dexS complexes, and another fraction forms chiCl–dexS polyelectrolyte
complexes. The elasticity values shown in the bottom of Fig. 11 indicate
that the addition of dexS to BLES–chiCl does not reduce the elasticity of
the surfactant preparation substantially for n−/n+ ratios lower than the
Fig. 11. Zeta potential (top) and dilatational elasticity (bottom) of preparations
containing 2.0 mg/ml BLES+0.15 mg/ml chiCl (protasan) in saline solution, as a
function of the ratio between the anionic groups from dexS and the cationic groups
from chiCl.
Fig. 12. Schematic of the binding of dexS to BLES–chiCl aggregates, and the chitosan
losses from the surfactant aggregates in the presence of excess dexS, leading to the
formation of chiCl–dexS complexes.
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reversal ratio, the elasticity of the ﬁlms decays substantially to values
close to the elasticity of BLES-alone ﬁlms [25,43]. This sharp decay in
elasticity suggests that the BLES–chiCl complex is being affected by the
presence of dexS. Certainly, as the n−/n+ ratios approach a value of 1, it
is more likely that the complex chiCl–dexS is favored over the complex
BLES–chiCl–dexS. This tendency of chiCl to bind exclusively to dexSwas
referred to as “chitosan removal” in the results section. This idea of
chitosan removal is illustrated in the schematic of Fig. 12.
The introduction of bicarbonate into the formulation increased the
pH of all the preparations. This increase in pH produced a decrease in
zeta potential for all formulations, an effect that is likely associated
with a reduction in the degree of ionization of chitosan chloride. A
review of the literature did not yield any reports on degree of
dissociation of chiCl with pH, but there is evidence that at pH values of
7 and higher chitosan hydrochlorides return to their insoluble
chitosan base form [52]. This increase in pH seems to affect the
binding of chiCl to BLES, as seen in the results of Table 1. The addition
of dextran sulfate, being a neutral salt, does not affect the pH of the
formulations, but it further reduces the zeta potential of the surfactant
aggregates. When dextran sulfate is added at concentrations low
enough to avoid chitosan removal (e.g. 0.04 mg/ml dexS), and added
before sodium bicarbonate it helps protect the BLES–chiCl binding.
This protective effect against the potential dissociative effect of higher
pHs suggests irreversible BLES–chiCl associations in the presence of
polyelectrolyte multilayers. Such irreversible effects have been
observed in other polyelectrolyte assemblies [53,54].
The variability of the performance of BLES batches evaluated in
ADSA–CSD at 100% R.H. and at the relatively low surfactant
concentration of 2 mg/ml (BLES clinical concentration ∼ 27 mg/ml)
has been reported before, as well as the use of chitosan to suppressthis variability [25]. Consistent with those observations, preparations
of BLES–chiCl formulated with different batches of BLES had similar
performance. However, the performance of BLES–chiCl–bicarbonate
was batch dependent. The reason for this variability is not understood
but it might be linked to the variability in the fraction of anionic lipids
and cationic peptides in BLES [2]. Furthermore, the importance of this
variability in clinical applications has not been established. On the
other hand, BLES–chiCl preparations containing an appropriate
concentration of dexS and enough bicarbonate to produce negatively
charged stable suspensions, maintain their surface active even when
using different BLES batches.
5. Conclusions
In this work it was shown that it is possible to use an anionic
polyelectrolyte, dextran sulfate (dexS), to restore the negative charge
(physiologically compatible) of surfactant aggregates prepared with
mixtures of BLES and chitosan hydrochloride (chiCl), while retaining
their surface activity. It was also determined that at high dexS/chiCl
ratios the preparations were less surface active and more susceptible
to serum inhibition. Introducing sodium bicarbonate to facilitate the
charge inversion of BLES–chiCl–dexS aggregates led to formulations
that retained their surface activity in the presence of serum used as
model inhibitor. These BLES–chiCl–dexS–bicarbonate preparations
produced stable milky suspensions that have the potential to be
effective in surfactant therapy.
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